Polymorph of Syk inhibitors
Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.
1. Polymorph Form 3 of a monohydrate bis-mesylate salt of a compound of Formula I
2. A pharmaceutical composition comprising:
Form 3 of a mononhydrate bis-mesylate salt of a compound of formula I:
and a pharmaceutical carrier, excipient, adjuvant, or vehicle.
3. The pharmaceutical composition of claim 2 , wherein the bis-mesylate salt is a monohydrate, bis-mesylate salt polymorph characterized by;
an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 13.8, 16.9, 22.9, and 26.1; or
an X-ray diffraction pattern substantially as shown in FIG. 1A or 1B .
4. The pharmaceutical composition of claim 2 , wherein the bis-mesylate salt is a monohydrate, bis-mesylate salt polymorph characterized by:
an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 13.8, 16.9, 22.9, and 26.1.
5. The pharmaceutical composition of claim 2 , wherein the bis-mesylate salt is a monohydrate, bis-mesylate salt polymorph characterized by an X-ray diffraction pattern substantially as shown in FIG. 1A .
6. The pharmaceutical composition of claim 2 , wherein the bis-mesylate salt is a monohydrate, bis-mesylate salt polymorph characterized by an X-ray diffraction pattern substantially as shown in FIG. 1B .
7. The polymorph of claim 1 , wherein said polymorph is characterized by an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 13.8, 16.9, 22.9, and 26.1.
8. The polymorph of claim 1 , wherein said polymorph is characterized by an Xray diffraction pattern substantially as shown in FIG. 1A .
9. The polymorph of claim 1 , wherein said polymorph is characterized by an X-ray diffraction pattern substantially as shown in FIG. 1B .